• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.迟发性运动障碍:当前治疗方法聚焦
Focus (Am Psychiatr Publ). 2021 Jan;19(1):14-23. doi: 10.1176/appi.focus.20200038. Epub 2021 Jan 25.
2
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.迟发性运动障碍的治疗:概述及重点关注囊泡单胺转运体 2 抑制剂。
Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x.
3
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.氘代丁苯那嗪用于治疗迟发性运动障碍患者的不自主运动。
Expert Rev Neurother. 2021 Jan;21(1):9-20. doi: 10.1080/14737175.2021.1848548. Epub 2020 Nov 23.
4
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.SLC18A2 基因与迟发性运动障碍的关联研究。
J Psychiatr Res. 2013 Nov;47(11):1760-5. doi: 10.1016/j.jpsychires.2013.07.025. Epub 2013 Sep 6.
5
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.与非典型抗精神病药物相关的迟发性运动障碍:患病率、发病机制和管理策略。
CNS Drugs. 2018 Feb;32(2):135-147. doi: 10.1007/s40263-018-0494-8.
6
A new era in the diagnosis and treatment of tardive dyskinesia.迟发性运动障碍诊断与治疗的新时代。
CNS Spectr. 2023 Aug;28(4):401-415. doi: 10.1017/S1092852922000992. Epub 2022 Oct 24.
7
Valbenazine for the treatment of tardive dyskinesia.用于治疗迟发性运动障碍的氘代丁苯那嗪
Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977.
8
Pathophysiology, prognosis and treatment of tardive dyskinesia.迟发性运动障碍的病理生理学、预后及治疗
Ther Adv Psychopharmacol. 2022 Oct 21;12:20451253221117313. doi: 10.1177/20451253221117313. eCollection 2022.
9
[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].[抗精神病药物所致精神分裂症性精神病的运动症状 - 第3部分:迟发性运动障碍]
Nervenarzt. 2019 May;90(5):472-484. doi: 10.1007/s00115-018-0629-7.
10
Deutetrabenazine in the treatment of tardive dyskinesia.丁苯那嗪治疗迟发性运动障碍
Neurodegener Dis Manag. 2019 Apr;9(2):59-71. doi: 10.2217/nmt-2018-0042. Epub 2019 Jan 31.

引用本文的文献

1
Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings.真实世界索赔分析以描述长期护理环境中迟发性运动障碍的负担
Neurol Ther. 2025 Sep 4. doi: 10.1007/s40120-025-00820-z.
2
Navigating the Novel Psychotropics.探索新型精神药物
Focus (Am Psychiatr Publ). 2021 Jan;19(1):1-2. doi: 10.1176/appi.focus.20200044. Epub 2021 Jan 25.

本文引用的文献

1
Management of Tardive Syndrome: Medications and Surgical Treatments.迟发性运动障碍的治疗:药物治疗和手术治疗。
Neurotherapeutics. 2020 Oct;17(4):1694-1712. doi: 10.1007/s13311-020-00898-3.
2
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.迟发性运动障碍的药物治疗:荟萃分析和系统评价。
J Clin Psychiatry. 2020 May 26;81(4):19r12798. doi: 10.4088/JCP.19r12798.
3
A unifying theory for the pathoetiologic mechanism of tardive dyskinesia.迟发性运动障碍病理病因机制的统一理论。
Med Hypotheses. 2020 Mar 16;140:109682. doi: 10.1016/j.mehy.2020.109682.
4
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.一项为期 1 年的 3 期、开放性标签试验,评估瓦伦贝扎在迟发性运动障碍成人患者中的应用。
J Clin Psychopharmacol. 2019 Nov/Dec;39(6):620-627. doi: 10.1097/JCP.0000000000001111.
5
Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.迟发性运动障碍对双相情感障碍、重性抑郁障碍和精神分裂症患者生活质量的影响。
Qual Life Res. 2019 Dec;28(12):3303-3312. doi: 10.1007/s11136-019-02269-8. Epub 2019 Aug 21.
6
Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.氯氮平和精神分裂症患者的迟发性运动障碍:系统评价。
J Psychopharmacol. 2019 Oct;33(10):1187-1198. doi: 10.1177/0269881119862535. Epub 2019 Jul 26.
7
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.盐酸曲司氯铵治疗逼尿肌过度活动症的长期安全性和有效性。
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10.
8
Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.重复经颅磁刺激治疗迟发性综合征:双盲随机临床试验。
J Neural Transm (Vienna). 2019 Feb;126(2):183-191. doi: 10.1007/s00702-018-1941-x. Epub 2018 Oct 13.
9
Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.氯氮平单药治疗抗精神病药引起的迟发性运动障碍:一项荟萃分析。
J Clin Psychiatry. 2018 Sep 18;79(6):17r11852. doi: 10.4088/JCP.17r11852.
10
Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial.神经刺激治疗迟发性运动障碍/运动障碍:延迟启动、假刺激对照随机试验。
Brain Stimul. 2018 Nov-Dec;11(6):1368-1377. doi: 10.1016/j.brs.2018.08.006. Epub 2018 Sep 11.

迟发性运动障碍:当前治疗方法聚焦

Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

作者信息

Debrey Sarah M, Goldsmith David R

机构信息

Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta.

出版信息

Focus (Am Psychiatr Publ). 2021 Jan;19(1):14-23. doi: 10.1176/appi.focus.20200038. Epub 2021 Jan 25.

DOI:10.1176/appi.focus.20200038
PMID:34483762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8412148/
Abstract

Tardive dyskinesia (TD) is a debilitating, iatrogenic, and potentially severe movement disorder characterized by involuntary, repetitive, purposeless movements that are present throughout the body. The authors present a review of studies of past, current, and possible future treatment approaches to the management of TD; consider the phenomenology, assessment, and putative pathophysiological mechanisms of TD, early pharmacological trials, a focus on the newer vesicular monoamine transporter 2 inhibitors, and other evidence-based approaches, such as clozapine; and present preliminary evidence for newer approaches, such as deep brain stimulation and repetitive transcranial magnetic stimulation. On the basis of the evidence presented here, the authors highlight the importance of early recognition and assessment of TD, as well as how to best approach management of these often incapacitating symptoms.

摘要

迟发性运动障碍(TD)是一种使人衰弱的医源性疾病,可能会发展为严重的运动障碍,其特征为全身出现不自主、重复性、无目的的运动。作者对过去、当前以及未来可能用于治疗TD的方法进行了综述;探讨了TD的症状表现、评估方法及假定的病理生理机制、早期药物试验、对新型囊泡单胺转运体2抑制剂的关注以及其他循证方法,如氯氮平;并介绍了一些新方法(如深部脑刺激和重复经颅磁刺激)的初步证据。基于本文所提供的证据,作者强调了早期识别和评估TD的重要性,以及如何最好地处理这些常常使人丧失能力的症状。